Aytu Biopharma (AYTU) Revenue (2013 - 2026)

Aytu Biopharma (AYTU) has 14 years of Revenue data on file, last reported at $12.4 million in Q1 2026.

• Revenue for Q1 2026 came in at $12.4 million, down 32.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $56.6 million (down 14.04% YoY), and the FY2025 annual result was $66.4 million, up 1.84% from the prior year.
• Revenue retreated to $12.4 million in Q1 2026 per AYTU's latest filing, from $15.2 million in the prior quarter.
• Over five years, Revenue peaked at $30.7 million in Q2 2023 and troughed at $12.4 million in Q1 2026.
• A 5-year average of $19.5 million and a median of $17.8 million in 2023 frame the typical range for Revenue.
• The sharpest annual moves came in 2024 and 2025: Revenue sank 52.52% in 2024, then jumped 31.57% in 2025.
• A 5-year view of Revenue shows it stood at $26.3 million in 2022, then dropped by 28.66% to $18.7 million in 2023, then declined by 13.48% to $16.2 million in 2024, then declined by 6.51% to $15.2 million in 2025, then fell by 18.16% to $12.4 million in 2026.
• Business Quant data shows AYTU's Revenue at $12.4 million in Q1 2026, $15.2 million in Q4 2025, and $13.9 million in Q3 2025.